ストックスクリーナーアプリを入手
36.97
1.68%
0.61
アフターアワーズ：
36.97
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Agios Pharmaceuticals Inc (AGIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Agios Pharmaceuticals Inc (AGIO) Cash Flow - TradingKey
Agios Pharmaceuticals Inc (AGIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Agios Pharmaceuticals Inc (AGIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Agios Pharmaceuticals Inc (AGIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AGIO|Agios Pharmaceuticals Inc|Price:36.360|Chg%:+0.080 - TradingKey
Agios Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AGIO - TradingView
Agios Pharmaceuticals Inc. (AGIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Agios Pharmaceuticals Inc (AGIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Imunon (IMNN) - The Globe and Mail
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Sahm
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program - Yahoo Finance
H.C. Wainwright lowers Agios Pharma price target to $52 on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Agios Pharma price target to $52 on trial data - Investing.com
Agios Pharmaceuticals (AGIO) Sees 13% Drop Following Trial Resul - GuruFocus
Agios Pharmaceuticals Reports Phase 2 Trial Results for Tebapiva - GuruFocus
Agios Pharmaceuticals (AGIO) Ends Development of Sickle Cell Dru - GuruFocus
AGIO Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Agios scraps sickle cell treatment after trial shows limited benefit - Reuters
Agios Pharmaceuticals stock falls on trial update - Investing.com
Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint - MedCity News
Agios pares loss after abandoning sickle cell asset tebapivat (AGIO:NASDAQ) - Seeking Alpha
Agios scraps sickle cell drug - BioPharma Dive
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move - Investor's Business Daily
Trial miss for Agios Pharma’s tebapivat in sickle cell disease - The Pharma Letter
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset - BioSpace
Agios Shelves Tebapivat In Sickle Cell, Weeks After MDS Exit - insights.citeline.com
Why Is AGIO Stock Falling Today? - TradingView
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO) - Yahoo Finance
Agios halts tebapivat development in sickle cell disease - Investing.com
Agios halts tebapivat development in sickle cell disease By Investing.com - Investing.com Nigeria
Agios Pharmaceuticals stock falls on trial update By Investing.com - Investing.com Canada
Agios Pharmaceuticals Reports Phase 2 Tebapivat Sickle Cell Disease Results, Discontinues Development of the Candidate - Quiver Quantitative
Agios Pharmaceuticals Shares Down 12.6% Prema - Moomoo
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease - The Manila Times
Tebapivat 5 mg Arm: 47.1% Hemoglobin Response; Agios Won’t Advance - Stock Titan
Agios Pharmaceuticals (AGIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
The Bull Case For Agios Pharmaceuticals (AGIO) Could Change Following FDA Priority Review For Mitapivat In Sickle Cell - simplywall.st
Agios gains FDA priority review for Pyrukynd label expansion - MSN
The Technical Signals Behind (AGIO) That Institutions Follow - Stock Traders Daily
Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued? - Sahm
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - AOL.com
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $54 - Moomoo
AGIO 260717 45.00P (AGIO260717P45000) Latest Announcements - Moomoo
Agios Pharmaceuticals (NASDAQ: AGIO) director reports 1,447-share equity award and 2,894 RSUs - Stock Titan
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week - AOL.com
Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat? - Yahoo Finance
Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease - Yahoo Finance
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up - The Globe and Mail
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):